

Liraglutide-¹³C₅,¹⁵N TFA

Cat. No.:	HY-P0014S1	
Molecular Formula:	C ₁₆₇ ¹³ C ₅ H ₂₆₅ N ₄₂ ¹⁵ NO ₅₁ ·xH ₂ ·yF ₃ O ₂	
Sequence:	His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-{Val-13C5,15N}-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-[Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly (TFA salt)	N6-[N-(1-oxohexadecyl)-L-γ-glutamyl] HAEGTFTSDV SSYLEGQAAK EFIGLVRGR G (TFA salt)
Sequence Shortening:	HAEGTFTSD-{Val-13C5,15N}-SSYLQAA-[Lys-N6-[N-(1-oxohexadecyl)-L-g-glutamyl]]-E FIAWLVRGRG (TFA salt)	
Target:	Isotope-Labeled Compounds	
Pathway:	Others	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY

Description	Liraglutide- ¹³ C ₅ , ¹⁵ N (tetraTFA) is the ¹³ C and ¹⁵ N labeled Liraglutide (HY-P0014) ^[1] . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus ^[2] .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA